Zimmer Biomet Holdings (ZBH) is a US-listed Healthcare company in Medical - Devices with a market capitalization of
7.1B, trading at $88.16 on the NYSE. This SniperIQ fundamentals page covers Zimmer Biomet Holdings's valuation (P/E 22.8x, P/B 1.4x), profitability (net margin 9.1%), revenue ($8.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market Cap
7.1B
P/E (TTM)22.8x
Net Margin9.1%
Revenue (FY25)$8.2B
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is Zimmer Biomet Holdings's market cap?
Zimmer Biomet Holdings (ZBH) has a market capitalization of approximately
7.1B, trading at $88.16 on the NYSE. Market cap moves with the live share price.
What is Zimmer Biomet Holdings's P/E ratio?
Zimmer Biomet Holdings's trailing twelve-month P/E ratio is 22.8x, with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Zimmer Biomet Holdings?
Zimmer Biomet Holdings runs a net profit margin of 9.1%, a gross margin of 70.0%, and an operating margin of 15.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Zimmer Biomet Holdings generate?
Zimmer Biomet Holdings reported revenue of $8.2B for fiscal year 2025, with net income of $705M and earnings per share (EPS) of 3.56. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Zimmer Biomet Holdings pay a dividend?
Zimmer Biomet Holdings offers a trailing dividend yield of about 1.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Zimmer Biomet Holdings financially healthy?
Zimmer Biomet Holdings carries a debt-to-equity ratio of 0.59x and a current ratio of 1.73x, with a market beta of 0.46. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Zimmer Biomet Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Zimmer Biomet Holdings (ZBH) the key facts are: market cap
7.1B, P/E 22.8x, revenue $8.2B, 52-week range 79.12-108.29. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Zimmer Biomet Holdings's full fundamentals live
Get Zimmer Biomet Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.